Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Cash & Equivalents (2019 - 2025)

Korro Bio (KRRO) has disclosed Cash & Equivalents for 6 consecutive years, with $24.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 61.78% year-over-year to $24.2 million, compared with a TTM value of $24.2 million through Sep 2025, down 61.78%, and an annual FY2024 reading of $55.6 million, down 66.51% over the prior year.
  • Cash & Equivalents was $24.2 million for Q3 2025 at Korro Bio, down from $33.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $169.2 million in Q1 2021 and bottomed at $24.2 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $75.1 million, with a median of $55.6 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents crashed 70.55% in 2022, then soared 357.3% in 2023.
  • Year by year, Cash & Equivalents stood at $79.6 million in 2021, then tumbled by 54.38% to $36.3 million in 2022, then skyrocketed by 357.3% to $166.2 million in 2023, then tumbled by 66.51% to $55.6 million in 2024, then plummeted by 56.59% to $24.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for KRRO at $24.2 million in Q3 2025, $33.6 million in Q2 2025, and $64.1 million in Q1 2025.